The Ratings Game: Biogen’s key Alzheimer’s disease drug is facing potential signs of trouble [MarketWatch]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: MarketWatch
Biogen’s key Alzheimer’s disease drug is facing potential signs of trouble Biogen Inc.’s crucial Alzheimer’s disease drug aducanumab is still a year or two from releasing key clinical trial results, but the company’s latest news may leave some investors feeling more circumspect. Because the company saw “more variability on the primary endpoint than assumed,” Biogen BIIB, +0.94% decided to increase the sample size of two ongoing trials by about 255 patients each, Chief Medical Officer Alfred Sandrock said at a Leerink Partners conference on Wednesday. The change, done to maintain 90% statistical power for the study, won’t affect the study’s blinded nature, which refers to how neither patients nor doctors know which is the drug and which is the placebo, Sandrock said. He also suggested that the decision shouldn’t raise questions about the therapy’s effectiveness. Read: Biogen in promising but risky limelight after Eli Lilly’s Alzheimer’s drug fails “We don’t know the treatment eff
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- UPDATE 2-India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says [Yahoo! Finance]Yahoo! Finance
- New Weight-Loss, Diabetes Drugs Reach One in Eight Americans [BNN Bloomberg (Canada)]BNN Bloomberg
- 3 Stocks to Buy Following Guidance Upgrades [Yahoo! Finance]Yahoo! Finance
- The finance chief of this biotech company is a Harvard-trained neuroscientist who says ‘the modern day CFO needs to speak the language of the team' [Fortune]Fortune
- Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 4/30/24 - Beat
LLY
Sec Filings
- 5/9/24 - Form 8-K
- 5/3/24 - Form SD
- 4/30/24 - Form 10-Q
- LLY's page on the SEC website